
Vortex Keratopathy in a Patient Receiving Vandetanib for Non-Small Cell Lung Cancer
- Jeeyun Ahn Won Ryang Wee Jin Hak Lee Joon Young Hyon
- 대한안과학회
- The Korean Journal of Ophthalmology
- Vol.25 No.5
- 등재여부 : KCI등재
- 2011.10
- 355 - 357 (3 pages)
We report a case of vortex keratopathy in a patient treated with vandetanib for non-small cell lung cancer (NSCLC). A 44-year-old female who underwent two cycles of chemotherapy for NSCLC complained of visual blurring in both eyes after the initiation of vandetanib, an anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor receptor 2 protein tyrosine kinase inhibitor. On ophthalmic examination, visual acuities were 20 / 20 OU and, with the exception of diffuse vortex keratopathy in both eyes, other findings were unremarkable. Vandetanib is believed to have caused vortex keratopathy in this patient. Anti-EGFR properties affecting normal corneal epithelial cell migration and wound healing or drug associated metabolite deposition, which is the case in numerous drug-associated vortex keratopathies, may be possible underlying mechanisms in the formation of this corneal complication.
Case Report
Discussion
Conflict of Interest
References